LIVN
NasdaqLivaNova PLC
Technology · Electromedical & Electrotherapeutic Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$1.0B
2021
$1.0B
2022
$1.2B
2023
$1.3B
2024
$1.4B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$1.4B
Net Income$-242.5M
Gross Profit$939.9M
Oper Income$199.4M
EPS (dil)$-4.45
Rev/sh$25.27
FCF/sh$3.15
Book/sh$21.84
Gross M67.7%
Oper M14.4%
Profit M-17.5%
FCF M12.5%
ROE-20.2%
ROA-9.3%
ROIC22.5%
R&D/Rev13.4%
Rev Y/Y10.7%
Rev 3Y CAGR10.8%
EPS Y/Y-483.6%
EPS 3Y CAGR—
FCF 3Y CAGR58.6%
Payout—
Div/sh—
Shs Chg Y/Y0%
Current Ratio1.36
Quick Ratio1.16
Debt/Eq0.34
Int Coverage4.0×
Net Debt$228.0M cash
Total Debt$407.5M
Cash & Eq$635.6M
Total Assets$2.6B
Oper CF$254.3M
Capex$81.0M
Free CF$173.3M
Buybacks$0
Equity$1.2B
Liabilities$1.4B
Shs Outstand0.05B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $1.0B | $1.2B | $1.3B | $1.4B |
| Gross Profit | $706.0M | $707.2M | $755.8M | $853.5M | $939.9M |
| Operating Income | $-784,000 | $-76.8M | $-68.5M | $129.1M | $199.4M |
| Net Income | $-135.8M | $-86.2M | $17.6M | $63.2M | $-242.5M |
| Diluted EPS | $-2.68 | $-1.61 | $0.32 | $1.16 | $-4.45 |
| Operating Cash Flow | $102.5M | $69.9M | $74.9M | $183.0M | $254.3M |
| Free Cash Flow | $77.1M | $43.4M | $39.9M | $135.9M | $173.3M |
COMMUNITY · $LIVN0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.